A citation-based method for searching scientific literature

Fatima Cardoso, Laura J van't Veer, Jan Bogaerts, Leen Slaets, Giuseppe Viale, Suzette Delaloge, Jean-Yves Pierga, Etienne Brain, Sylvain Causeret, Mauro DeLorenzi, Annuska M Glas, Vassilis Golfinopoulos, Theodora Goulioti, Susan Knox, Erika Matos, Bart Meulemans, Peter A Neijenhuis, Ulrike Nitz, Rodolfo Passalacqua, Peter Ravdin, Isabel T Rubio, Mahasti Saghatchian, Tineke J Smilde, Christos Sotiriou, Lisette Stork, Carolyn Straehle, Geraldine Thomas, Alastair M Thompson, Jacobus M van der Hoeven, Peter Vuylsteke, René Bernards, Konstantinos Tryfonidis, Emiel Rutgers, Martine Piccart. N Engl J Med 2016
Times Cited: 862







List of co-cited articles
593 articles co-cited >1



Times Cited
  Times     Co-cited
Similarity


Adjuvant Chemotherapy Guided by a 21-Gene Expression Assay in Breast Cancer.
Joseph A Sparano, Robert J Gray, Della F Makower, Kathleen I Pritchard, Kathy S Albain, Daniel F Hayes, Charles E Geyer, Elizabeth C Dees, Matthew P Goetz, John A Olson,[...]. N Engl J Med 2018
866
48

Supervised risk predictor of breast cancer based on intrinsic subtypes.
Joel S Parker, Michael Mullins, Maggie C U Cheang, Samuel Leung, David Voduc, Tammi Vickery, Sherri Davies, Christiane Fauron, Xiaping He, Zhiyuan Hu,[...]. J Clin Oncol 2009
20

A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer.
Soonmyung Paik, Steven Shak, Gong Tang, Chungyeul Kim, Joffre Baker, Maureen Cronin, Frederick L Baehner, Michael G Walker, Drew Watson, Taesung Park,[...]. N Engl J Med 2004
20

Molecular portraits of human breast tumours.
C M Perou, T Sørlie, M B Eisen, M van de Rijn, S S Jeffrey, C A Rees, J R Pollack, D T Ross, H Johnsen, L A Akslen,[...]. Nature 2000
19

20-Year Risks of Breast-Cancer Recurrence after Stopping Endocrine Therapy at 5 Years.
Hongchao Pan, Richard Gray, Jeremy Braybrooke, Christina Davies, Carolyn Taylor, Paul McGale, Richard Peto, Kathleen I Pritchard, Jonas Bergh, Mitch Dowsett,[...]. N Engl J Med 2017
569
16

Comparison of the Performance of 6 Prognostic Signatures for Estrogen Receptor-Positive Breast Cancer: A Secondary Analysis of a Randomized Clinical Trial.
Ivana Sestak, Richard Buus, Jack Cuzick, Peter Dubsky, Ralf Kronenwett, Carsten Denkert, Sean Ferree, Dennis Sgroi, Catherine Schnabel, Frederick L Baehner,[...]. JAMA Oncol 2018
151
16

A gene-expression signature as a predictor of survival in breast cancer.
Marc J van de Vijver, Yudong D He, Laura J van't Veer, Hongyue Dai, Augustinus A M Hart, Dorien W Voskuil, George J Schreiber, Johannes L Peterse, Chris Roberts, Matthew J Marton,[...]. N Engl J Med 2002
15

Use of Biomarkers to Guide Decisions on Adjuvant Systemic Therapy for Women With Early-Stage Invasive Breast Cancer: ASCO Clinical Practice Guideline Update-Integration of Results From TAILORx.
Fabrice Andre, Nofisat Ismaila, N Lynn Henry, Mark R Somerfield, Robert C Bast, William Barlow, Deborah E Collyar, M Elizabeth Hammond, Nicole M Kuderer, Minetta C Liu,[...]. J Clin Oncol 2019
101
14

Prospective Validation of a 21-Gene Expression Assay in Breast Cancer.
Joseph A Sparano, Robert J Gray, Della F Makower, Kathleen I Pritchard, Kathy S Albain, Daniel F Hayes, Charles E Geyer, Elizabeth C Dees, Edith A Perez, John A Olson,[...]. N Engl J Med 2015
771
14

Prognostic and predictive value of the 21-gene recurrence score assay in postmenopausal women with node-positive, oestrogen-receptor-positive breast cancer on chemotherapy: a retrospective analysis of a randomised trial.
Kathy S Albain, William E Barlow, Steven Shak, Gabriel N Hortobagyi, Robert B Livingston, I-Tien Yeh, Peter Ravdin, Roberto Bugarini, Frederick L Baehner, Nancy E Davidson,[...]. Lancet Oncol 2010
939
13

Gene expression profiling predicts clinical outcome of breast cancer.
Laura J van 't Veer, Hongyue Dai, Marc J van de Vijver, Yudong D He, Augustinus A M Hart, Mao Mao, Hans L Peterse, Karin van der Kooy, Matthew J Marton, Anke T Witteveen,[...]. Nature 2002
13

Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient-level meta-analysis of randomised trials.
C Davies, J Godwin, R Gray, M Clarke, D Cutter, S Darby, P McGale, H C Pan, C Taylor, Y C Wang,[...]. Lancet 2011
13

Early breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up†.
F Cardoso, S Kyriakides, S Ohno, F Penault-Llorca, P Poortmans, I T Rubio, S Zackrisson, E Senkus. Ann Oncol 2019
450
13

Comparisons between different polychemotherapy regimens for early breast cancer: meta-analyses of long-term outcome among 100,000 women in 123 randomised trials.
R Peto, C Davies, J Godwin, R Gray, H C Pan, M Clarke, D Cutter, S Darby, P McGale, C Taylor,[...]. Lancet 2012
13

Gene expression and benefit of chemotherapy in women with node-negative, estrogen receptor-positive breast cancer.
Soonmyung Paik, Gong Tang, Steven Shak, Chungyeul Kim, Joffre Baker, Wanseop Kim, Maureen Cronin, Frederick L Baehner, Drew Watson, John Bryant,[...]. J Clin Oncol 2006
12

Development and verification of the PAM50-based Prosigna breast cancer gene signature assay.
Brett Wallden, James Storhoff, Torsten Nielsen, Naeem Dowidar, Carl Schaper, Sean Ferree, Shuzhen Liu, Samuel Leung, Gary Geiss, Jacqueline Snider,[...]. BMC Med Genomics 2015
224
12

Clinical and Genomic Risk to Guide the Use of Adjuvant Therapy for Breast Cancer.
Joseph A Sparano, Robert J Gray, Peter M Ravdin, Della F Makower, Kathleen I Pritchard, Kathy S Albain, Daniel F Hayes, Charles E Geyer, Elizabeth C Dees, Matthew P Goetz,[...]. N Engl J Med 2019
179
12


A new molecular predictor of distant recurrence in ER-positive, HER2-negative breast cancer adds independent information to conventional clinical risk factors.
Martin Filipits, Margaretha Rudas, Raimund Jakesz, Peter Dubsky, Florian Fitzal, Christian F Singer, Otto Dietze, Richard Greil, Andrea Jelen, Paul Sevelda,[...]. Clin Cancer Res 2011
399
11

Estimating the benefits of therapy for early-stage breast cancer: the St. Gallen International Consensus Guidelines for the primary therapy of early breast cancer 2019.
H J Burstein, G Curigliano, S Loibl, P Dubsky, M Gnant, P Poortmans, M Colleoni, C Denkert, M Piccart-Gebhart, M Regan,[...]. Ann Oncol 2019
258
11

Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications.
T Sørlie, C M Perou, R Tibshirani, T Aas, S Geisler, H Johnsen, T Hastie, M B Eisen, M van de Rijn, S S Jeffrey,[...]. Proc Natl Acad Sci U S A 2001
10

Abemaciclib Combined With Endocrine Therapy for the Adjuvant Treatment of HR+, HER2-, Node-Positive, High-Risk, Early Breast Cancer (monarchE).
Stephen R D Johnston, Nadia Harbeck, Roberto Hegg, Masakazu Toi, Miguel Martin, Zhi Min Shao, Qing Yuan Zhang, Jorge Luis Martinez Rodriguez, Mario Campone, Erika Hamilton,[...]. J Clin Oncol 2020
132
10

70-gene signature as an aid for treatment decisions in early breast cancer: updated results of the phase 3 randomised MINDACT trial with an exploratory analysis by age.
Martine Piccart, Laura J van 't Veer, Coralie Poncet, Josephine M N Lopes Cardozo, Suzette Delaloge, Jean-Yves Pierga, Peter Vuylsteke, Etienne Brain, Suzan Vrijaldenhoven, Peter A Neijenhuis,[...]. Lancet Oncol 2021
32
31

Comparison of PAM50 risk of recurrence score with oncotype DX and IHC4 for predicting risk of distant recurrence after endocrine therapy.
Mitch Dowsett, Ivana Sestak, Elena Lopez-Knowles, Kalvinder Sidhu, Anita K Dunbier, J Wayne Cowens, Sean Ferree, James Storhoff, Carl Schaper, Jack Cuzick. J Clin Oncol 2013
392
9



21-Gene Assay to Inform Chemotherapy Benefit in Node-Positive Breast Cancer.
Kevin Kalinsky, William E Barlow, Julie R Gralow, Funda Meric-Bernstam, Kathy S Albain, Daniel F Hayes, Nancy U Lin, Edith A Perez, Lori J Goldstein, Stephen K L Chia,[...]. N Engl J Med 2021
22
40

The EndoPredict score provides prognostic information on late distant metastases in ER+/HER2- breast cancer patients.
P Dubsky, J C Brase, R Jakesz, M Rudas, C F Singer, R Greil, O Dietze, I Luisser, E Klug, R Sedivy,[...]. Br J Cancer 2013
198
8

PAM50 Risk of Recurrence Score Predicts 10-Year Distant Recurrence in a Comprehensive Danish Cohort of Postmenopausal Women Allocated to 5 Years of Endocrine Therapy for Hormone Receptor-Positive Early Breast Cancer.
Anne-Vibeke Lænkholm, Maj-Britt Jensen, Jens Ole Eriksen, Birgitte Bruun Rasmussen, Ann S Knoop, Wesley Buckingham, Sean Ferree, Carl Schaper, Torsten O Nielsen, Taryn Haffner,[...]. J Clin Oncol 2018
58
13

Hallmarks of cancer: the next generation.
Douglas Hanahan, Robert A Weinberg. Cell 2011
8

Prognostic value of a combined estrogen receptor, progesterone receptor, Ki-67, and human epidermal growth factor receptor 2 immunohistochemical score and comparison with the Genomic Health recurrence score in early breast cancer.
Jack Cuzick, Mitch Dowsett, Silvia Pineda, Christopher Wale, Janine Salter, Emma Quinn, Lila Zabaglo, Elizabeth Mallon, Andrew R Green, Ian O Ellis,[...]. J Clin Oncol 2011
485
8

Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis.
Patricia Cortazar, Lijun Zhang, Michael Untch, Keyur Mehta, Joseph P Costantino, Norman Wolmark, Hervé Bonnefoi, David Cameron, Luca Gianni, Pinuccia Valagussa,[...]. Lancet 2014
8


West German Study Group Phase III PlanB Trial: First Prospective Outcome Data for the 21-Gene Recurrence Score Assay and Concordance of Prognostic Markers by Central and Local Pathology Assessment.
Oleg Gluz, Ulrike A Nitz, Matthias Christgen, Ronald E Kates, Steven Shak, Michael Clemens, Stefan Kraemer, Bahriye Aktas, Sherko Kuemmel, Toralf Reimer,[...]. J Clin Oncol 2016
154
7

Breast Cancer-Major changes in the American Joint Committee on Cancer eighth edition cancer staging manual.
Armando E Giuliano, James L Connolly, Stephen B Edge, Elizabeth A Mittendorf, Hope S Rugo, Lawrence J Solin, Donald L Weaver, David J Winchester, Gabriel N Hortobagyi. CA Cancer J Clin 2017
367
7

Prediction of risk of distant recurrence using the 21-gene recurrence score in node-negative and node-positive postmenopausal patients with breast cancer treated with anastrozole or tamoxifen: a TransATAC study.
Mitch Dowsett, Jack Cuzick, Christopher Wale, John Forbes, Elizabeth A Mallon, Janine Salter, Emma Quinn, Anita Dunbier, Michael Baum, Aman Buzdar,[...]. J Clin Oncol 2010
494
7

Prediction of late distant recurrence in patients with oestrogen-receptor-positive breast cancer: a prospective comparison of the breast-cancer index (BCI) assay, 21-gene recurrence score, and IHC4 in the TransATAC study population.
Dennis C Sgroi, Ivana Sestak, Jack Cuzick, Yi Zhang, Catherine A Schnabel, Brock Schroeder, Mark G Erlander, Anita Dunbier, Kally Sidhu, Elena Lopez-Knowles,[...]. Lancet Oncol 2013
245
7

Validation and clinical utility of a 70-gene prognostic signature for women with node-negative breast cancer.
Marc Buyse, Sherene Loi, Laura van't Veer, Giuseppe Viale, Mauro Delorenzi, Annuska M Glas, Mahasti Saghatchian d'Assignies, Jonas Bergh, Rosette Lidereau, Paul Ellis,[...]. J Natl Cancer Inst 2006
788
7

Computer program to assist in making decisions about adjuvant therapy for women with early breast cancer.
P M Ravdin, L A Siminoff, G J Davis, M B Mercer, J Hewlett, N Gerson, H L Parker. J Clin Oncol 2001
684
7

Use of Molecular Tools to Identify Patients With Indolent Breast Cancers With Ultralow Risk Over 2 Decades.
Laura J Esserman, Christina Yau, Carlie K Thompson, Laura J van 't Veer, Alexander D Borowsky, Katherine A Hoadley, Nicholas P Tobin, Bo Nordenskjöld, Tommy Fornander, Olle Stål,[...]. JAMA Oncol 2017
50
14

Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles.
Aravind Subramanian, Pablo Tamayo, Vamsi K Mootha, Sayan Mukherjee, Benjamin L Ebert, Michael A Gillette, Amanda Paulovich, Scott L Pomeroy, Todd R Golub, Eric S Lander,[...]. Proc Natl Acad Sci U S A 2005
7

The genomic and transcriptomic architecture of 2,000 breast tumours reveals novel subgroups.
Christina Curtis, Sohrab P Shah, Suet-Feung Chin, Gulisa Turashvili, Oscar M Rueda, Mark J Dunning, Doug Speed, Andy G Lynch, Shamith Samarajiwa, Yinyin Yuan,[...]. Nature 2012
7

Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries.
Freddie Bray, Jacques Ferlay, Isabelle Soerjomataram, Rebecca L Siegel, Lindsey A Torre, Ahmedin Jemal. CA Cancer J Clin 2018
7

Trastuzumab Emtansine for Residual Invasive HER2-Positive Breast Cancer.
Gunter von Minckwitz, Chiun-Sheng Huang, Max S Mano, Sibylle Loibl, Eleftherios P Mamounas, Michael Untch, Norman Wolmark, Priya Rastogi, Andreas Schneeweiss, Andres Redondo,[...]. N Engl J Med 2019
737
7

Palbociclib with adjuvant endocrine therapy in early breast cancer (PALLAS): interim analysis of a multicentre, open-label, randomised, phase 3 study.
Erica L Mayer, Amylou C Dueck, Miguel Martin, Gabor Rubovszky, Harold J Burstein, Meritxell Bellet-Ezquerra, Kathy D Miller, Nicholas Zdenkowski, Eric P Winer, Georg Pfeiler,[...]. Lancet Oncol 2021
59
11

Palbociclib for Residual High-Risk Invasive HR-Positive and HER2-Negative Early Breast Cancer-The Penelope-B Trial.
Sibylle Loibl, Frederik Marmé, Miguel Martin, Michael Untch, Hervé Bonnefoi, Sung-Bae Kim, Harry Bear, Nicole McCarthy, Mireia Melé Olivé, Karen Gelmon,[...]. J Clin Oncol 2021
35
20

Tailoring Adjuvant Endocrine Therapy for Premenopausal Breast Cancer.
Prudence A Francis, Olivia Pagani, Gini F Fleming, Barbara A Walley, Marco Colleoni, István Láng, Henry L Gómez, Carlo Tondini, Eva Ciruelos, Harold J Burstein,[...]. N Engl J Med 2018
239
7

Prognostic utility of HOXB13:IL17BR and molecular grade index in early-stage breast cancer patients from the Stockholm trial.
P-L Jerevall, X-J Ma, H Li, R Salunga, N C Kesty, M G Erlander, D C Sgroi, B Holmlund, L Skoog, T Fornander,[...]. Br J Cancer 2011
122
6

Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 10-year analysis of the ATAC trial.
Jack Cuzick, Ivana Sestak, Michael Baum, Aman Buzdar, Anthony Howell, Mitch Dowsett, John F Forbes. Lancet Oncol 2010
569
6

Clinical validation of the EndoPredict test in node-positive, chemotherapy-treated ER+/HER2- breast cancer patients: results from the GEICAM 9906 trial.
Miguel Martin, Jan C Brase, Lourdes Calvo, Kristin Krappmann, Manuel Ruiz-Borrego, Karin Fisch, Amparo Ruiz, Karsten E Weber, Blanca Munarriz, Christoph Petry,[...]. Breast Cancer Res 2014
81
7


Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.